An investigational monoclonal antibody selectively targeting Siglec-8, an inhibitory receptor found on mast cells and eosinophils
Eosinophilic Gastrointestinal Diseases (EGIDs)
Phase 2 study met all prespecified primary and secondary endpoints, Phase 3 study initiated
Clinical activity demonstrated in multiple mast cell and eosinophil driven diseases